Immunologic Findings in B-Chronic Lymphocytic Leukemia Patients Treated with α_2b-Interferon

References

• Neidhart J. A., Gagen M. M., Young D., Tuttle R., Melink T. J., Ziccarelli A., Kisner D. Interferon a therapy of renal cancer. Cancer Res. 1984; 44: 4140–3
   PubMed Web of Science ®Google Scholar
• Quesada J. R., Reuben J., Manning J. T., Hersch E. M., Gutterman J. U. Alpha interferon for induction of remission in hairy-cell leukemia. New Engl. J. Med. 1984; 310: 15–8
   PubMed Web of Science ®Google Scholar
• Pangalis G. A., Kittas Ch., Viniou N., Kokkinou S., Variamis H., Paizis P., Melanthiou F., Fessas Ph. Hairy cell leukemia: Bone marrow changes following splenctomy and α-interferon therapy. Leukemia 1987; 1: 343–6
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., McCredie K., Trujillo J. M., Keating M. J., Gutterman J. U. Hematologic remission and cytoogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N. Engl. J. Med. 1986; 314: 1065–9
   PubMed Web of Science ®Google Scholar
• Gutterman J. U., Blumenschein G., Alexanian R., Yap H. Y., Buzdar A. U., Cabanillas F., Hortobagyi G. N., Hersh E. M., Rasmussen S. L., Harmon M., Kramer M., Pestka S. Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann. Intern. Med. 1980; 93: 399–403
   PubMed Web of Science ®Google Scholar
• Bellardelli F., Gresser I., Maury C., Maunoury M. T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms. Int. J. Cancer 1982; 30: 813–20
   PubMed Web of Science ®Google Scholar
• Gresser I., Thomas M. T., Brouty-Boye D. Effects of interferon treatment of L 1210 cells in vitro on tumor and colony formation. Nature New Biol. 1971; 231: 20–1
   PubMedGoogle Scholar
• Pangalis G. A., Griva E. Recombinant α2b-interferon therapy in untreated stages A and B chronic lymphocytic leukemia. A preliminary report. Cancer 1988; 61: 869–72
   PubMed Web of Science ®Google Scholar
• Rozman C., Montserrat E., Vinolas N., Urbano-Ispizua A., Ribera J. M., Gallart T., Compernolle C. Recombinant α2-interferon in the treatment of B-chronic lymphocytic leukemia in early stages. Blood 1988; 71(5)1295–8
   PubMed Web of Science ®Google Scholar
• Talpaz M., Rosenblum M., Kurzock R., Reuben J., Kantarjian H., Gutterman J. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia-A pilot study. Am. J. Hematol. 1987; 23: 341–4
   Web of Science ®Google Scholar
• Boussiotis V. A., Pangalis G. A. Randomized clinical trial with α2b-interferon in 26 stage A untreated B-chronic lymphocytic leukemia patients. Nouv. Rev. Fr. Hematol. 1988; 30: 471–3
   PubMedGoogle Scholar
• Foon K. A., Bottino C., Abrams P. C., Fer M. F., Longo D. L., Schoenberg C. S., Oldman R. K. Phase II trial of recombinant leukocyte A interferon in patients with chronic lymphocytic leukemia. Am. J. Med. 1985; 78: 216–20
   PubMed Web of Science ®Google Scholar
• Ostlund L., Einhorn S., Robert K-H, Juliusson G., Biberfeld P. Chronic B-lymphocytic leukemia cells proliferate and differentiate following exposure to interferon in vitro. Blood 1986; 67(1)152–9
   PubMed Web of Science ®Google Scholar
• Fellous M., Kamoun M., Gresser I., Bono R. Enhanced expression of HLA antigens and β2-microglobulin on interferon treated human lymphoid cells. Eur. J. Immun. 1979; 9: 446–9
   PubMed Web of Science ®Google Scholar
• Ogawa Y., Horrike N., Onji M., Michitaka K., Ohta Y. Interferon therapy in patients with HBeAg-positive chronic active hepatitis. J. Med. Virol. 1987; 21(4)121A
   Web of Science ®Google Scholar
• Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 1985; 135: 3172–7
   PubMed Web of Science ®Google Scholar
• MacKeen L., Brown M. C., Kung P. C., Yasuda N., Harrington D., Hinuma Y., Weisenburger D., Lai P., Purtilo D. Serum interleukin-2 receptor as a marker for active T cell malignancies. Fed. Proc. 1986; 45: 454–7
   Google Scholar
• Semenzato G., Foa R., Agostini C., Zambello R., Trentin L., Vinante F., Benedetti F., Chilosi M., Pizzolo G. High serum levels of soluble interleukin-2 receptors in patients with B-chronic lymphocytic leukemia. Blood 1987; 70: 396–400
   PubMed Web of Science ®Google Scholar
• Richards J. M., Latta J. M., Golomb H. M. Correlation of serum levels of soluble interleukin-2 receptor with response and relapse of hairy cell leukemia. Blood 1988; 72(5)223a, (Suppl. 1)
   Google Scholar
• Panayiotides P., Lenkei R., Portwit A., Reizenstein P. Malignant B cells have receptors for and respond to interleukin-2. Med. Oncol. Tumor Pharmacother. 1986; 3(3/4)255–63
   PubMedGoogle Scholar
• Zaknoen S. L., Suen R., Oken M. M., Kay N. E. Expression of mRNA for IL-2 receptor and secretion of soluble IL-2 receptor (p55) from malignant B cells of B-CLL. Blood 1988; 72(5)260a, (Suppl. 1)
   Google Scholar
• Tomkinson B., Brown M. C., Ip S, Sullivan J. L. Released CD8 levels in immune activation. 2nd Annual Conference on Clinical Immunology, Washington, DC, 1987, Abstract
   Google Scholar
• Chiorazzi N., Fu S. M., Montazeri G., Kunkel H. G., Rai K., Gee T. T cell helper defect in patients with chronic lymphocytic leukemia. J. Immunol. 1979; 122: 1087–90
   PubMed Web of Science ®Google Scholar
• Platsoukas C. D., Galinski M., Kempin S., Reich L., Clark-son B., Good R. A. Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: An analysis by monoclonal antibodies. J. Immunol. 1982; 129: 2305–12
   PubMed Web of Science ®Google Scholar
• Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Farrar J. F. The Biochemistry, Biology and role of interleukin-2 in the induction of cytotoxic T-cell and antibody forming B cell responses. Immunological Rev. 1982; 63: 129–158
   PubMed Web of Science ®Google Scholar
• Foa R., Giovarelli M., Jemma C., Fierro M. T., Lusso P., Ferrando M. L., Lauria F., Forni G. Interleukin-2 (IL-2) and interferon-V production by T lymphocytes from patients with B-chronic lymphocytic leukemia: Evidence that normally released IL-2 is absorbed by the neoplastic B cell population. Blood 1985; 66: 614–9
   PubMed Web of Science ®Google Scholar